Scientists have been searching for treatments for neurodegenerative disorders like& Alzheimer's and Parkinson's for many years... | Genetics And Genomics ...

The biopharmaceutical industry's increasing reliance on organoids for drug discovery and validation is another vital factor propelling market growth. These 3D structures enable hi ...

KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease ...